Last updated on November 2019

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)


Brief description of study

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Clinical Study Identifier: NCT02568267

Find a site near you

Start Over

Yale University

New Haven, CT United States
  Connect »

Karmanos Cancer Center

Detroit, MI United States
  Connect »

Levine Cancer Institute

Charlotte, NC United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

Austin Hospital

Heidelberg, Australia
  Connect »

Liverpool Hospital

Liverpool, Australia
  Connect »

Newcastle Private Hospital

New Lambton Heights, Australia
  Connect »

Mayo Clinic

Scottsdale, AZ United States
  Connect »

Scripps Clinic

La Jolla, CA United States
  Connect »

UCSF Mount Zion Medical Ctr

San Francisco, CA United States
  Connect »

Sarcoma Oncology Center

Santa Monica, CA United States
  Connect »

Cleveland Clinic Florida

Weston, FL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

North Shore Hem Onc Associates

East Setauket, NY United States
  Connect »

Duke Cancer Institute

Durham, NC United States
  Connect »

OSU, James Cancer Hospital

Columbus, OH United States
  Connect »

Asan Medical Center.

Seoul, Korea, Republic of
  Connect »

Winship Cancer Institute

Atlanta, GA United States
  Connect »

Washington University

Saint Louis, MO United States
  Connect »

Oregon Health & Science Univ

Portland, OR United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »